Back to Authors

Dumitrescu, Logan

0000-0002-9782-9944

Mayo Clinic

Vanderbilt Memory and Alzheimer's Center, Vanderbilt Health, Nashville, TN, 37203, USA.

Citations 4

Combining post-mortem and neuroimaging measures of brain amyloidosis to accelerate genomic discovery
Wang, Ting‐Chen , Ali, Muhammad, Wu, Yiyang , Mormino, Elizabeth, Buckley, Rachel F. , Saykin, Andrew J, Jager, Philip L. De , Schneider, Julie A, Vardarajan, Badri, Mayeux, Richard, Kunkle, Brian W, Keene, C Dirk, Seshadri, S, Sperling, Reisa A, Kamboh, M Ilyas, Jagust, William J. , Schellenberg, Gerard D, Huentelman, MJ, Hamilton-Nelson, Kara, Pericak-Vance, Margaret A, Haines, Jonathan L, Montine, Thomas J, Beecham, Gary, Archer, Derek , Wu, Yiyang , Buckley, Rachel F , De Jager, Philip L , Bennett, David A. , Barnes, Lisa L , Bush, William S , Vemuri, Prashanthi , Ramanan, Vijay K , Harrison, Theresa M , Jagust, William J , Laws, Simon M , Below, Jennifer E , Cruchaga, Carlos , Seto, Mabel , Dumitrescu, Logan , Archer, Derek B. , Ali, Muhammad , Mormino, Elizabeth C. , Lee, Annie , Saykin, Andrew J. , Schneider, Julie A. , Bennett, David A. , Barnes, Lisa L. , Vardarajan, Badri Narayan , Mayeux, Richard , Kunkle, Brian W. , Bush, William S. , Keene, C Dirk, Sperling, Reisa Anne , Vemuri, Prashanthi , Ramanan, Vijay K. , Kamboh, M. Ilyas , Harrison, Theresa M. , Schellenberg, Gerard D. , Hamilton‐Nelson, Kara L. , Pericak‐Vance, Margaret A. , Goate, Alison , Haines, Jonathan L. , Montine, Thomas J. , Beecham, Gary W. , Hohman, Timothy J. , Dumitrescu, Logan

Brain | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag216 Get It

Abstract Histopathological assessment has served as the gold standard for diagnosing Alzheimer’s disease (AD). Emerging technological advancements, including the development of amyloid positron emission tomography (PET), have enabled early detection of amyloid pathology, one of the neuropathological hallmarks of AD. Genome-wide association study (GWAS) across cohorts of aging and AD, leveraging different measurements of amyloid burden, may facilitate the identification of novel genetic variants that drive the earliest neuropathological changes in AD. This study presents the largest GWAS of brain amyloidosis to date, leveraging amyloid β (Aβ) measured by in vivo amyloid PET and postmortem histopathology from 13,555 individuals of European ancestry. Amyloid positivity was defined as moderate or frequent neuritic plaques according to the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) staging scores for each postmortem cohort. A Gaussian mixture model (GMM) was applied to each amyloid PET cohort to identify the cohort and tracer-specific cut-offs that differentiate amyloid positive and negative populations. In silico and ex vivo analyses further characterized implicated loci, including interrogating the association between bulk and single-nucleus gene expression profiles and AD-related traits. Genetic covariance analysis assessed the extent amyloid PET and postmortem measures reflect the shared genetic architecture of brain amyloidosis. Our combined amyloidosis GWAS identified three established AD risk loci: BIN1 (rs6733839, OR = 1.20, 95% CI 1.14-1.26, P = 1.32 × 10−11), CR1 (rs4844610, OR = 1.24, 95% CI = 1.16-1.32, P = 4.21 × 10−10), APOE (rs429358, OR = 4.01, 95% CI = 3.66-4.38, P = 4.54 × 10−201), and a newly identified brain amyloidosis-associated variant on chromosome 17 (rs35635959, OR = 1.18, 95% CI = 1.12-1.25, P = 1.47 × 10−8). SuSiE fine-mapping identified a single credible set of 15 putative causal variants with rs35635959 as the lead variant. Subsequent eQTL and SuSiE-based colocalization analyses prioritized rs35635959 as a strong eQTL for TUBG2, encoding tubulin gamma 2, which is involved in microtubule organization and synaptic plasticity. Further cell-type-specific characterization of this gene in neurons from dorsolateral prefrontal cortex tissue indicated that decreased TUBG2 expression was associated with increased Aβ burden and AD case status (PFDR < 0.045). Furthermore, our study is the first to report a modest genetic covariance (covariance=0.17, P < 6.54 × 10−8) between the genetic architecture of amyloid burden captured by different modalities. While APOE showed a strong association with both amyloid endophenotypes, the observed genetic covariance was not substantially attenuated after excluding variants within the APOE region (covariance=0.16, P < 1.32 × 10−7). Our results highlight the benefits of leveraging compatible, harmonized AD endophenotypes to increase power to uncover new molecular insights into the etiology of AD neuropathology. Wang et al. present the largest GWAS of brain amyloidosis to date, analysing 13,555 individuals using amyloid PET and postmortem Aβ measures. They identify a novel amyloidosis-associated variant on chromosome 17, demonstrate genetic covariance between modalities, and highlight complex traits sharing genetic architecture with Aβ burden.
An APOE *4-Informed Genomic Atlas of the X Chromosome in Alzheimer’s Disease
Cook, Noah , Zeng, Youjie , Yang, Chenyu , Jiang, Zhiwen , Wang, Ting‐Chen , Guen, Yann Le , Cody, Karly Alex , Johnson, Matthew, Zhang, Rui, Merritt, Victoria C. , Hauger, Richard L. , Program, the VA Million Veteran, FinnGen, Koran, Mary Ellen, Mormino, Elizabeth C. , Gordon, Brian , DeCasien, Alex, Andrews, Shea J. , Logue, Mark, Greicius, Michael D. , Le Guen, Yann , Cody, Karly A , Koran, Mary Ellen , Gordon, Brian A , Andrews, Shea , Dumitrescu, Logan , Archer, Derek , Seto, Mabel , Pottier, Cyril , Cruchaga, Carlos , Sherva, Richard , Logue, Mark W. , Napolioni, Valerio , Belloy, Michael E , Cook, Noah , Zeng, Youjie , Yang, Chenyu , Zhang, Rui, Merritt, Victoria C. , Hauger, Richard L. , Koran, Mary Ellen I. , Mormino, Elizabeth C. , DeCasien, Alex R. , Dumitrescu, Logan , Archer, Derek B. , Hohman, Timothy J. , Belloy, Michaël E.

No container title available | May 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.05.26352461 Get It

Abstract The genetic contributions of the X chromosome to Alzheimer’s disease (AD) remain poorly understood yet are expected to importantly shape sex differences in AD. We therefore performed large-scale X-chromosome-wide association studies (N=1,240,451), evaluating differential risk due to sex, APOE *4, and escape from X-chromosome inactivation, finding most X-linked loci appear relevant to female-biased AD etiology. In evaluating genetic pleiotropy with hormonal, lipid, and brain imaging traits, we discovered X-linked AD loci converged on white matter traits, particularly in the anterior corona radiata and splenium of the corpus callosum. Through brain-centric functional genomics analyses, we then nominated candidate causal genes, including 5 that appeared highly robust. Notably, we found the escape gene RBBP7 decreases AD risk in APOE *4 carriers likely through higher expression in excitatory neurons to counter tau-related neurodegeneration. Altogether, we provide an atlas of sex and APOE *4-informed candidate X-linked AD risk loci, genes, and mechanisms that will guide future studies.
Exploring common genetic contributors to neuroprotection from amyloid pathology
Seto, Mabel , Mahoney, Emily R. , Dumitrescu, Logan , Ramanan, Vijay K. , Deming, Yuetiva, Albert, Marilyn, Zetterberg, Henrik , Blennow, Kaj , Vemuri, Prashanthi , Jefferson, Angela L. , Hohman, Timothy J. , Initiative, for the Alzheimer’s Disease Neuroimaging, Seto, Mabel , Deming, Yuetiva , Zetterberg, Henrik , Vemuri, Prashanthi , Ramanan, Vijay K , Dumitrescu, Logan , Engelman, Corinne D. , Johnson, Sterling C. , Initiative, for the Alzheimer’s Disease Neuroimaging

Brain Communications | March 15, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcac066 Get It

Abstract Preclinical Alzheimer’s disease describes some individuals who harbour Alzheimer’s pathologies but are asymptomatic. For this study, we hypothesized that genetic variation may help protect some individuals from Alzheimer’s-related neurodegeneration. We therefore conducted a genome-wide association study using 5 891 064 common variants to assess whether genetic variation modifies the association between baseline beta-amyloid, as measured by both cerebrospinal fluid and positron emission tomography, and neurodegeneration defined using MRI measures of hippocampal volume. We combined and jointly analysed genotype, biomarker and neuroimaging data from non-Hispanic white individuals who were enrolled in four longitudinal ageing studies (n = 1065). Using regression models, we examined the interaction between common genetic variants (Minor Allele Frequency >0.01), including APOE-ɛ4 and APOE-ɛ2, and baseline cerebrospinal levels of amyloid (CSF Aβ42) on baseline hippocampal volume and the longitudinal rate of hippocampal atrophy. For targeted replication of top findings, we analysed an independent dataset (n = 808) where amyloid burden was assessed by Pittsburgh Compound B ([11C]-PiB) positron emission tomography. In this study, we found that APOE-ɛ4 modified the association between baseline CSF Aβ42 and hippocampal volume such that APOE-ɛ4 carriers showed more rapid atrophy, particularly in the presence of enhanced amyloidosis. We also identified a novel locus on chromosome 3 that interacted with baseline CSF Aβ42. Minor allele carriers of rs62263260, an expression quantitative trait locus for the SEMA5B gene (P = 1.46 × 10−8; 3:122675327) had more rapid neurodegeneration when amyloid burden was high and slower neurodegeneration when amyloid was low. The rs62263260 × amyloid interaction on longitudinal change in hippocampal volume was replicated in an independent dataset (P = 0.0112) where amyloid burden was assessed by positron emission tomography. In addition to supporting the established interaction between APOE and amyloid on neurodegeneration, our study identifies a novel locus that modifies the association between beta-amyloid and hippocampal atrophy. Annotation results may implicate SEMA5B, a gene involved in synaptic pruning and axonal guidance, as a high-quality candidate for functional confirmation and future mechanistic analysis.